National and regional differences in meningococcal vaccine recommendations for individuals at an increased risk of meningococcal disease
Introduction Invasive meningococcal disease (IMD) is a severe, life-threatening condition caused by infection with Neisseria meningitidis. Currently available vaccines offer protection against the five most common meningococcal disease-causing serogroups and include monovalent and quadrivalent conju...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Expert Review of Vaccines |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/14760584.2023.2245467 |
| _version_ | 1797633685390884864 |
|---|---|
| author | Cynthia Burman Jamie Findlow Helen S. Marshall Marco A.P. Safadi |
| author_facet | Cynthia Burman Jamie Findlow Helen S. Marshall Marco A.P. Safadi |
| author_sort | Cynthia Burman |
| collection | DOAJ |
| description | Introduction Invasive meningococcal disease (IMD) is a severe, life-threatening condition caused by infection with Neisseria meningitidis. Currently available vaccines offer protection against the five most common meningococcal disease-causing serogroups and include monovalent and quadrivalent conjugate vaccines (MenA, MenC, MenACWY vaccines) and outer membrane vesicle- and/or recombinant protein-based vaccines (MenB vaccines). Areas covered Country and regional immunization programs target populations susceptible to IMD and typically emphasize the highest-risk age groups (i.e., infants, adolescents/young adults, and the elderly); however, additional groups are also considered at an elevated risk and are the focus of the current review. Specific increased-risk groups include individuals with underlying immunocompromising medical conditions, university/college students, Indigenous people, laboratory workers, military personnel, men who have sex with men, and travelers to areas with hyperendemic IMD. This review compares established meningococcal vaccination recommendations for these vulnerable groups in Europe, the United States, Australia, New Zealand, Israel, Brazil, and Turkey. Expert opinion Recommendations should be standardized to cover all groups at increased risk of IMD. |
| first_indexed | 2024-03-11T11:58:21Z |
| format | Article |
| id | doaj.art-0028005609cf427382b799e17f619924 |
| institution | Directory Open Access Journal |
| issn | 1476-0584 1744-8395 |
| language | English |
| last_indexed | 2024-03-11T11:58:21Z |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Expert Review of Vaccines |
| spelling | doaj.art-0028005609cf427382b799e17f6199242023-11-08T11:40:02ZengTaylor & Francis GroupExpert Review of Vaccines1476-05841744-83952023-12-0122183984810.1080/14760584.2023.22454672245467National and regional differences in meningococcal vaccine recommendations for individuals at an increased risk of meningococcal diseaseCynthia Burman0Jamie Findlow1Helen S. Marshall2Marco A.P. Safadi3Pfizer IncPfizer Ltd, TadworthThe University of AdelaideSanta Casa de São Paulo School of Medical SciencesIntroduction Invasive meningococcal disease (IMD) is a severe, life-threatening condition caused by infection with Neisseria meningitidis. Currently available vaccines offer protection against the five most common meningococcal disease-causing serogroups and include monovalent and quadrivalent conjugate vaccines (MenA, MenC, MenACWY vaccines) and outer membrane vesicle- and/or recombinant protein-based vaccines (MenB vaccines). Areas covered Country and regional immunization programs target populations susceptible to IMD and typically emphasize the highest-risk age groups (i.e., infants, adolescents/young adults, and the elderly); however, additional groups are also considered at an elevated risk and are the focus of the current review. Specific increased-risk groups include individuals with underlying immunocompromising medical conditions, university/college students, Indigenous people, laboratory workers, military personnel, men who have sex with men, and travelers to areas with hyperendemic IMD. This review compares established meningococcal vaccination recommendations for these vulnerable groups in Europe, the United States, Australia, New Zealand, Israel, Brazil, and Turkey. Expert opinion Recommendations should be standardized to cover all groups at increased risk of IMD.http://dx.doi.org/10.1080/14760584.2023.2245467increased riskmenacwymenbvaccinevaccine recommendations |
| spellingShingle | Cynthia Burman Jamie Findlow Helen S. Marshall Marco A.P. Safadi National and regional differences in meningococcal vaccine recommendations for individuals at an increased risk of meningococcal disease Expert Review of Vaccines increased risk menacwy menb vaccine vaccine recommendations |
| title | National and regional differences in meningococcal vaccine recommendations for individuals at an increased risk of meningococcal disease |
| title_full | National and regional differences in meningococcal vaccine recommendations for individuals at an increased risk of meningococcal disease |
| title_fullStr | National and regional differences in meningococcal vaccine recommendations for individuals at an increased risk of meningococcal disease |
| title_full_unstemmed | National and regional differences in meningococcal vaccine recommendations for individuals at an increased risk of meningococcal disease |
| title_short | National and regional differences in meningococcal vaccine recommendations for individuals at an increased risk of meningococcal disease |
| title_sort | national and regional differences in meningococcal vaccine recommendations for individuals at an increased risk of meningococcal disease |
| topic | increased risk menacwy menb vaccine vaccine recommendations |
| url | http://dx.doi.org/10.1080/14760584.2023.2245467 |
| work_keys_str_mv | AT cynthiaburman nationalandregionaldifferencesinmeningococcalvaccinerecommendationsforindividualsatanincreasedriskofmeningococcaldisease AT jamiefindlow nationalandregionaldifferencesinmeningococcalvaccinerecommendationsforindividualsatanincreasedriskofmeningococcaldisease AT helensmarshall nationalandregionaldifferencesinmeningococcalvaccinerecommendationsforindividualsatanincreasedriskofmeningococcaldisease AT marcoapsafadi nationalandregionaldifferencesinmeningococcalvaccinerecommendationsforindividualsatanincreasedriskofmeningococcaldisease |